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OBJECTIVE— We investigated the relation between soluble CD36 (sCD36), risk markers of
atherosclerosis and body composition, and glucose and lipid metabolism in polycystic ovary
syndrome (PCOS).
RESEARCH DESIGN AND METHODS— Thirty PCOS patients were randomized to
30 mg/day pioglitazone or placebo for 16 weeks. Fourteen weight-matched healthy female
subjects were included as control subjects. sCD36, oxidized LDL (oxLDL), high-sensitivity
C-reactive protein (hsCRP), interleukin (IL)-6, euglycemic-hyperinsulinemic clamps, and
whole-body dual-energy X-ray absorptiometry scans were performed.
RESULTS— sCD36 (2.87 relative units [0.88–9.36] vs. 1.67 relative units [0.72–3.89]),
oxLDL (44.9 units/l [26.9–75.1] vs. 36.1 units/l [23.4–55.5]), and hsCRP (0.26 mg/dl [0.03–
2.41] vs. 0.12 mg/dl [0.02–0.81]) were significantly increased in PCOS patients versus control
subjects (geometric mean  2 SD). In PCOS, positive correlations were found between central
fat mass and sCD36 (r  0.43), hsCRP (r  0.43), and IL-6 (r  0.42) (all P  0.05). After
adjusting for fat mass, sCD36 and oxLDL correlated inversely with measures of insulin-
stimulated glucose metabolism and positively with lipid oxidation during insulin stimulation in
PCOS patients and control subjects (n  44). sCD36 and oxLDL were significant independent
predictors of glucose and lipid metabolism, whereas hsCRP and IL-6 showed no significant
contribution.
Following pioglitazone treatment, insulin sensitivity increased, whereas sCD36 (3.21 relative
units [0.76–13.6] vs. 2.33 relative units [0.84–6.46]) and hsCRP decreased (P  0.05). No
significant changes were measured in body composition.
CONCLUSIONS— sCD36 and oxLDL correlated with measures of insulin sensitivity inde-
pendent of central fat mass. Pioglitazone treatment reduced sCD36 while improving insulin-
stimulated glucose metabolism, further supporting the association between sCD36 and insulin
resistance in PCOS.
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Polycystic ovary syndrome (PCOS) ischaracterized by anovulation, hy-perandrogenemia, and/or polycystic
ovaries. About 50% of PCOS patients ful-
fill the criteria of the metabolic syndrome.
A five- to eightfold increased risk for type
2 diabetes in PCOS patients compared
with weight-matched female control sub-
jects makes the syndrome of high socio-
economic importance (1). Previous
studies found significantly increased risk
of hypertension and coronary heart dis-
ease in women with irregular cycles, sug-
gesting a 4- to 11-fold increased risk for
coronary heart disease (2). Increased risk
factors for coronary heart disease in PCOS
patients were documented in several pre-
vious studies, including atherogenic lipid
profiles, increased coronary artery calcifi-
cation, and echocardiographic abnormal-
ities (3).
Abdominal obesity is seen in over-
weight and in most normal-weight PCOS
patients. Abdominal obesity, especially
visceral adiposity, is associated with insu-
lin resistance and increased levels of in-
flammatory markers including high-
sensitive C-reactive protein (hsCRP) and
cytokines. Previous studies (4,5) reported
higher levels of inflammatory markers in
PCOS patients compared with weight-
matched control subjects.
CD36 is expressed on the surface of
monoytes and macrophages (6). CD36
may initiate atherosclerotic lesions and be
an important risk factor of cardiovascular
disease (6). The foam-cell formation pro-
cess is initiated and enhanced by the
binding of oxidized LDL (oxLDL) to
CD36 receptors (6). In mice lacking the
CD36 receptor, foam-cell formation and
vascular lesion development are inter-
rupted (7).
In ob/ob mice, increased CD36 ex-
pression on macrophages was caused by
defective insulin signaling, which was re-
verted during peroxisome proliferator–
activated receptor- agonist treatment
(8). These results suggested important re-
lations between decreased insulin sensi-
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tivity, foam-cell formation, and, possibly,
future atherosclerosis
Based on a hypothesis that CD36
could be released into circulation as
part of a low-grade inflammatory state
with increased macrophage activation
in patients with type 2 diabetes, Hand-
berg et al. (9) developed an assay for the
measurement of soluble CD36 (sCD36)
in plasma. Handberg et al. found a sig-
nificant inverse correlation between
sCD36 and insulin-stimulated glucose
disposal. sCD36 correlated positively
with insulin and BMI, but no measures
of central fat mass were performed. BMI
and fasting plasma glucose were inde-
pendent predictors of sCD36 levels,
thus suggesting a correlation between
obesity, poor glycemic control, and ac-
celerated atherosclerosis risk in patients
with type 2 diabetes (9).
Increased insulin sensitivity and de-
creased insulin levels are followed by im-
proved ovulatory function in PCOS. Few
studies exist evaluating the effects of per-
oxisome proliferator–activated recep-
tor- treatment on inflammatory markers
in PCOS (10,11). In the present study, we
tested the hypothesis that PCOS patients
had significantly higher sCD36 levels
than control subjects and that sCD36 cor-
related with fat mass and measures of glu-
cose metabolism. oxLDL, hsCRP, and
interleukin (IL)-6 levels were furthermore
included to evaluate possible mecha-
nisms for increased inflammation in
PCOS and how this is affected by peroxi-
some proliferator–activated receptor-
treatment.
RESEARCH DESIGN AND
METHODS— The study subjects
have previously been described in two
articles on insulin sensitivity, IGF-1,
and growth hormone levels during pio-
glitazone treatment in PCOS patients
(12,13). In brief, 30 reproductive-age
Caucasian women with PCOS were in-
cluded. Criteria for PCOS were irregu-
lar periods with cycle length 35 days
and testosterone above reference inter-
val and/or hirsutism. Included patients
had elevated fasting insulin and/or were
obese. Fourteen healthy, Caucasian,
premenopausal women matched to
PCOS patients for BMI and age were
studied as control subjects. All control
subjects had regular menses (period
lengths 28 –34 days) and did not suffer
from hyperandrogenemia or hirsutism.
The study was approved by the local
ethics committee and by the Danish
Medicines Agency, and all subjects gave
written informed consent.
After initial examination (see descrip-
tion below), patients were randomized to
30 mg/day pioglitazone (Actos; Takeda,
Lilly) or placebo in a double-blind fashion
(treatment modality blinded for patients
and doctors). After a treatment period of
16 weeks, patients were admitted for re-
peated examinations similar to the initial
evaluation program. Two patients were
excluded from the study. One patient in
the placebo group became pregnant and
one patient on pioglitazone treatment ex-
perienced side effects (dizziness, ankle
edema, and anxiety) and was excluded af-
ter 1 week of treatment.
Examinations
Examinations were performed during the
follicular phase in patients with oligo-
menorrhea. Patients with amenorrhea
(period length 3 months) were exam-
ined randomly. The evaluation program
of included subjects was performed as
previously described (12,13).
Clinical examination. Included sub-
jects underwent a clinical examination in-
cluding establishment of Ferriman-
Gallwey score, BMI, waist-to-hip ratio,
height, and weight.
Whole-body dual-energy X-ray absorp-
tiometry scan. Dual-energy X-ray ab-
sorptiometry in whole-body array mode
(Hologic QDR-4500) was used to mea-
sure whole-body fat mass and to differen-
tiate between extremital and central fat
mass. The coefficient of variation (CV) for
replicate scans of the same individual was
0.8% for whole-body fat mass.
Euglycemic-hyperinsulinemic clamp.
The clamp protocol has previously been
described (13). In brief, after a 120-min
basal tracer equilibration period, insulin
(Actrapid; Novo Nordisk, Bagsvaerd,
Denmark) was infused at a rate of 40
mU/m2 per min for 180 min, and plasma
glucose levels were clamped at 5
mmol/l using a variable infusion rate of
20% glucose. 3-3H glucose was added to
the glucose infusate to maintain constant
levels of plasma-specific activity during
the clamp period. Indirect calorimetry
was performed during the last 40 min of
the basal and insulin infusion periods us-
ing a ventilated hood system (Deltatrac 2;
SensorMedics, Yorba Linda, CA), and av-
erage gas exchanges were used to calcu-
late glucose and lipid oxidation rates and
total energy expenditure.
Calculations
Steele’s non–steady state formulas were
used to calculate rates of total glucose ap-
pearance (Ra) and glucose disposal (Rd),
assuming a glucose distribution volume
of 200 ml/kg body wt and a pool fraction
of 0.65. Nonoxidative glucose metabo-
lism was calculated as the difference
between Rd and glucose oxidation deter-
mined by indirect calorimetry. Glucose
infusion rate during the last 20 min of the
insulin infusion period was used for cal-
culation of whole-body insulin sensitivity
(Si). Si was calculated as the glucose infu-
sion rate divided by the incremental in-
crease in insulin concentration from the
basal to the insulin-stimulated period
during the clamp and divided by the
mean glucose concentration during the
last 40 min of the insulin clamp.
Assays
Sex hormones
Serum total testosterone was analyzed us-
ing a specific radioimmunoassay after ex-
traction as previously described (14).
This method has a close correlation with
the determination of testosterone levels
using mass spectrometry. Sex hormone–
binding globulin was analyzed by a
time-resolved immunoassay using a Au-
toDELFIA commercial kit (Wallac Oy,
Turku, Finland). The intra-assay CV for
total testosterone was 8.2% and for sex
hormone–binding globulin 5.2%. The in-
terassay CV for total testosterone was
13.8% and for sex hormone– binding
globulin 7.5%.
Plasma free fatty acids, sCD36,
oxLDL, hsCRP, and IL-6
Plasma free fatty acids (FFAs) were ana-
lyzed by enzymatic colonimetric reac-
tions (Modular P; Roche). sCD36 was
measured using an in-house enzyme-
linked immunosorbent assay (ELISA) (9).
A pool of EDTA plasma, aliquoted and
stored in the80°C freezer, was analyzed
in seven dilutions in each run and used as
a standard concentration curve. Two di-
lutions of another EDTA pool were used
as internal controls, and each control was
run in quadruplicates on each ELISA
plate. Patient EDTA plasma samples were
analyzed in duplicates. Total CV was
11.9–17.3%.
oxLDL was measured in plasma by a
competitive ELISA (Mercodia, Uppsala,
Sweden) with a total CV of 6.5–9.6%.
hsCRP was measured by a solid-phase,
chemiluminescent immunometric assay
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(Immulite 2000) with a within-run CV of
2.8–8.7% and a total CV of 3.1–8.7%.
IL-6 was determined by a high-sensitivity
solid-phase ELISA from R&D (Abingdon,
U.K.). Intra-assay CV was 6.9–7.8%, and
interassay CV was 6.5–9.6%, according to
the manufacturer.
Statistical analysis
Fasting and insulin-stimulated hormonal
and metabolic variables and sCD36, ox-
LDL, hsCRP, and IL-6 levels were approx-
imately log-Gaussian distributed. Data
were backtransformed and presented a
geometric mean (2 SD), as previously
described by Altman (15). Pretreatment
differences between PCOS patients in the
pioglitazone and placebo group and con-
trol subjects were tested using unpaired t
tests on log-transformed values.
Basal differences between patients
randomized to pioglitazone and placebo
were taken into account by comparing 
values of hormonal and metabolic vari-
ables between the placebo and pioglita-
zone groups using Mann-Whitney U
tests.
The relationship between pretreat-
ment levels of sCD36, oxLDL, hsCRP,
IL-6, and metabolic and body composi-
tion variables were evaluated by Spear-
man’s nonparametric correlation tests.
Body composition parameters were en-
tered in the analyses (BMI, waist-to-hip
ratio, and total and central fat mass). En-
tered measures of metabolic parameters
were Si, Rd, insulin-stimulated oxidative
and nonoxidative glucose metabolism,
lipid oxidation, and FFA levels during in-
sulin stimulation.
Correlations between the individual
markers sCD36, oxLDL, hsCRP, or IL-6
and glucose and lipid metabolism were
corrected for BMI or central fat mass using
multiple regression analyses. In each
analysis, the logarithm of one of the
parameters Si, Rd, insulin-stimulated oxi-
dative and nonoxidative glucose metabo-
lism, lipid oxidation, or FFA levels during
insulin stimulation was entered as the de-
pendent variable. As independent vari-
ables, BMI or central fat mass and one of
the markers sCD36, oxLDL, hsCRP, or
IL-6 were entered in each analysis. In this
way, two independent variables (one
measure of fat mass and one marker of
inflammation/insulin resistance) were en-
tered in each analysis.
The contribution of sCD36, oxLDL,
hsCRP, and IL-6 to measures of glucose
and lipid metabolism were furthermore
evaluated using multiple regression. TheT
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same dependent variables were entered as
described above (Si, Rd, insulin-stimulated
oxidative and nonoxidative glucose metab-
olism, lipid oxidation, or FFA levels during
insulin stimulation), whereas all the mea-
sures sCD36, oxLDL, hsCRP, and IL-6 were
entered at the same time as independent
variables. All statistics were performed
using SPSS 13.0 (SPSS, Chicago, IL) for
calculations, and P values 0.05 were
considered significant.
RESULTS
Glucose metabolism, body
composition, and hormonal
parameters in PCOS patients and
control subjects
PCOS patients had higher levels of free
testosterone than control subjects (Table
1). During the insulin-stimulated state,
PCOS patients had higher FFA levels and
rates of lipid oxidation and lower Si, Rd,
and oxidative and nonoxidative glucose
metabolism than control subjects (all P
0.001).
Pioglitazone treatment improved Si,
insulin-stimulated Rd, oxidative and non-
oxidative glucose metabolism, and the
ability of insulin to suppress FFA and
lipid oxidation when compared with
changes during placebo. No significant
changes were observed in testosterone
levels and body composition.
sCD36, oxLDL, hsCRP, and IL-6
levels in PCOS patients versus
control subjects: effect of
pioglitazone and placebo treatment
Pretreatment levels of sCD36, oxLDL,
and hsCRP were increased in PCOS pa-
tients versus control subjects, whereas no
significant differences were found in IL-6
levels. sCD36 and hsCRP decreased dur-
ing pioglitazone treatment when com-
pared with changes during placebo
treatment.
sCD36, oxLDL, hsCRP, and IL-6
levels and body composition and
metabolic parameters
Representative scatter plots with correla-
tions between sCD36 and metabolic vari-
ables in control subjects and PCOS
patients are shown in Fig. 1.
sCD36
In PCOS patients (n 30), sCD36 signif-
icantly correlated with central fat mass
(r  0.43, P  0.02), insulin-stimulated
oxidative glucose metabolism (r 
0.57, P  0.001), and lipid oxidation
during insulin stimulation (r 0.53, P
0.003). When pooling patients and con-
trol subjects (n  44), significant inverse
correlations were found between sCD36
and Si (r0.53), insulin-stimulated Rd
(r  0.55), insulin-stimulated glucose
oxidation (r  0.66) (all P  0.001),
and insulin-stimulated nonoxidative glu-
cose metabolism (r  0.36, P  0.01).
Positive correlations were found between
sCD36 and FFA levels (r  0.54) and
lipid oxidation (r  0.69) during insulin
stimulation (both P  0.001).
oxLDL
The only significant correlation in PCOS
patients was between oxLDL and insulin-
stimulated nonoxidative glucose metabo-
Figure 1—Correlations between sCD36 and metabolic variables in PCOS patients and control
subjects. Bivariate correlation analyses between sCD36 and measures of glucose and lipid metab-
olism.R values and P levels are presented for Spearman’s nonparametric correlation tests in PCOS
patients and PCOS plus control subjects.f, PCOS;, control subjects. Regression lines: fat lines:
PCOS plus control subjects; dotted lines: PCOS.
Glintborg and Associates
DIABETES CARE, VOLUME 31, NUMBER 2, FEBRUARY 2008 331
lism (r  0.39, P  0.04). All other P
values for correlations between oxLDL
and metabolic parameters were 0.15,
and for correlations with fat mass mea-
sures P values were 0.5.
In PCOS and control subjects (n 
44), inverse correlations were found be-
tween oxLDL and measures of Si and in-
sulin-stimulated glucose metabolism (r
0.32 to 0.51, all P  0.03), and pos-
itive correlations were found with FFA
levels during insulin stimulation (r 
0.52, P  0.001).
hsCRP
In PCOS patients, hsCRP correlated with
all measures of body composition (r 
0.43–0.59, all P 0.01), whereas no sig-
nificant correlations were found with en-
tered metabolic parameters (all P  0.3).
In pooled PCOS and control subjects,
correlations between hsCRP and mea-
sures of body composition remained sig-
nificant (r  0.42–0.60, all P  0.005).
Inverse correlations were found between
hsCRP and insulin-stimulated oxidative
and nonoxidative glucose metabolism
(r  0.29 and 0.27, P  0.05), and
positive correlations were found with
FFA levels during insulin stimulation (r
0.39, P  0.009).
IL-6
Positive correlations were found between
IL-6 and all measures of body composi-
tion in PCOS patients as well as in PCOS
and control subjects (r  0.37–0.52, all
P  0.05), whereas no significant corre-
lations were found with metabolic param-
eters (all P  0.4).
Bivariate correlations between
sCD36, oxLDL, hsCRP, and IL-6
IL-6 showed a significant positive corre-
lation with hsCRP in both patients (r 
0.60, P 0.001) and in patients and con-
trol subjects (r 0.60, P 0.001). Oth-
erwise, no significant correlations were
found between inflammatory markers
(P  0.3).
Inflammatory markers in relation to
total and free testosterone levels
In PCOS patients, a positive correlation
was found between oxLDL and free tes-
tosterone (r  0.36, P  0.05), which
remained significant in pooled patient
and control subject data. No significant
correlations were found between sCD36,
hsCRP, or IL-6 and testosterone levels
(P  0.3).
BMI-adjusted correlations between
sCD36, oxLDL, hsCRP, or IL-6 and
glucose and lipid metabolism
sCD36 showed BMI-independent signifi-
cant inverse associations with Si, Rd, and
insulin-stimulated oxidative glucose me-
tabolism, whereas positive correlations
were found with FFAs and lipid oxidation
during insulin stimulation (Table 2). After
adjusting for BMI, oxLDL was inversely
correlated with Si, Rd, and insulin-
stimulated oxidative and nonoxidative
glucose metabolism, whereas a positive
BMI-independent correlation was found
with FFAs during insulin stimulation. In
all cases, similar correlation coefficients
and levels of significance were found
when entering central fat mass in regres-
sion analyses (data not shown). No signif-
icant associations were found when
entering hsCRP and IL-6 in multiple re-
gression analyses.
Contribution of sCD36, oxLDL,
hsCRP, and IL-6 to Si, glucose, and
lipid metabolism
sCD36 and oxLDL were significant inde-
pendent predictors of all measures of Si,
glucose, and lipid metabolism, whereas
hsCRP and IL-6 showed no significant
contribution. The proportion of the vari-
ation in glucose and lipid metabolism ex-
plained by the inflammatory markers
varied from 25% for lipid oxidation to
43% for Rd.
CONCLUSIONS— In the present
study, we applied the measurement of
sCD36 in PCOS at baseline and during
pioglitazone treatment. sCD36 showed
fat mass–independent correlations with
clamp-established measures of glucose
and lipid metabolism, and increased
sCD36 levels were significantly reversed
during pioglitazone-induced increased
insulin sensitivity. These results sup-
ported that sCD36 is an independent
marker of insulin resistance in PCOS.
Our findings of significant correla-
tions between sCD36 and measures of
glucose metabolism and FFAs in PCOS
patients and control subjects are in agree-
ment with the results of Handberg et al.
(9) in patients with type 2 diabetes.
sCD36 levels were significantly de-
creased, whereas no significant changes
were observed in central fat mass after
pioglitazone treatment. Multiple regres-
sion analyses further supported the fat
mass–independent correlation between
sCD36 and insulin sensitivity. However,
no direct measures of intra-abdominal
and subcutaneous fat mass were available
in the present study, and computed to-
mography or magnetic resonance scans
are needed to determine the relation be-
tween sCD36 levels and intra-abdominal
versus subcutaneous fat distribution in
PCOS patients.
Recent studies suggested that LDL
must be oxidized to be taken up by mac-
rophages, making oxLDL the atherogenic
form of LDL (16). Increased levels of ox-
LDL in PCOS patients compared with
weight-matched control subjects were
documented in a recent study (17) in
Table 2—BMI-corrected correlations between inflammatory markers and measures of insulin
sensitivity and glucose and lipid metabolism in PCOS patients and control subjects (n  44)
R2 model
(P values)
BMI-adjusted 

coefficient
(P values)
sCD36
Si 0.16 (0.03)* 0.38 (0.01)*
Rd 0.16 (0.03)* 0.027 (0.01)*
Insulin-stimulated oxidative glucose 0.21 (0.009)* 0.0028 (0.004)*
Insulin-stimulated FFAs 0.15 (0.04)* 0.03 (0.05)*
Insulin-stim lipid oxidation 0.13 (0.05)* 0.04 (0.02)*
oxLDL
Si 0.18 (0.01)* 0.008 (0.006)*
Rd 0.28 (0.001)† 0.008 (0.001)†
Insulin-stimulated oxidative glucose 0.13 (0.05)* 0.004 (0.03)*
Insulin-stimulated nonoxidative glucose 0.21 (0.009)* 0.01 (0.003)*
Insulin-stimulated FFAs 0.27 (0.001)† 0.009 (0.002)*
Entered dependent variables: logarithm of Si, insulin-stimulated Rd, insulin-stimulated oxidative and non-
oxidative glucose metabolism, and lipid oxidation and FFA levels during insulin stimulation. Entered
independent variables: BMI and one of the markers: sCD36, oxLDL, hsCRP, or IL-6. Only data from models
with significant R2 values are presented. *P  0.05; †P  0.001.
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overweight and normal-weight sub-
groups of PCOS patients. In this study,
Macut et al. (17) examined 179 PCOS pa-
tients (79 overweight and 100 normal
weight) and 56 (20 overweight and 36
normal weight) control subjects. PCOS
was defined according to the Rotterdam
criteria (18). Macut et al. found compara-
ble oxLDL levels in normal-weight and
overweight PCOS patients. These find-
ings suggested a minor association be-
tween body weight and oxLDL levels in
PCOS and are in agreement with the BMI-
independent correlation between oxLDL
and glucose and lipid metabolism in the
present study.
We found significant associations,
similar to those with sCD36, between ox-
LDL and measures of fat mass and glucose
and lipid metabolism. During multiple re-
gression analyses, sCD36 and oxLDL
were significant independent predictors
of glucose and lipid metabolism, whereas
hsCRP and IL-6 showed no significant
contribution. The lack of a direct relation-
ship between oxLDL and sCD36 indicates
that the underlying mechanism of ele-
vated sCD36 may be related to insulin re-
sistance rather than to increased oxLDL
levels per se.
In the present study, oxLDL showed a
significant positive correlation with free
testosterone, but this correlation became
insignificant after correcting for BMI.
These findings are supported by previous
studies in PCOS and suggest that the in-
crease in levels of oxLDL in PCOS more
closely relates to insulin resistance and
abdominal obesity than to hyperandro-
genemia (17,19).
hsCRP is secreted in response to cy-
tokines including IL-6. Previous studies
showed that a high hsCRP level was the
strongest univariate predictor for the risk
of cardiovascular events (rev. in 20).
hsCRP may not only be a marker of in-
flammatory disease but may also amplify
the inflammation process by further acti-
vation of monocytes and endothelial cells
(20). In the present study, significantly
higher hsCRP levels in PCOS patients
than in control subjects supported the in-
creased risk of atherosclerosis in PCOS.
Furthermore, significant positive correla-
tions between hsCRP and IL-6 and fat
mass measures in both patients and con-
trol subjects support a relationship be-
tween abdominal and overall fat mass and
hsCRP and IL-6. hsCRP and IL-6 were
increased in PCOS patients compared
with control subjects of matched body
composition and therefore suggested pos-
sible associations between hsCRP and
IL-6 and insulin sensitivity or hyperan-
drogenemia. We found no significant cor-
relations between hsCRP and testosterone
levels. Pioglitazone-mediated improved
insulin sensitivity was accompanied by
decreased hsCRP levels, whereas no sig-
nificant changes were measured in body
composition or testosterone levels. Over-
all, these findings suggest parallel im-
provements of insulin sensitivity and
hsCRP levels during pioglitazone treat-
ment. Supporting the relation between
hsCRP and IL-6, we found significant
positive correlations between these mark-
ers, although no significant improvement
of IL-6 levels was observed during piogli-
tazone treatment.
Some previous studies (21) have
found significantly increased hsCRP lev-
els in PCOS patients compared with
weight-matched control subjects, al-
though this could not be reproduced in
other studies (22,23). In agreement with
our study, two previous studies (22,23)
measured IL-6 levels in PCOS and found
no significant differences between PCOS
patients and control subjects. In one pre-
vious study by Puder et al. (21), the au-
thors included hsCRP, and a dual-energy
X-ray absorptiometry scan established
measures of fat mass in PCOS patients
and control subjects and found significant
correlations between hsCRP and fat mass
measures. As in the present study, most
previous studies were performed in small
study populations, and this may have af-
fected results.
In conclusion, hsCRP and IL-6 levels
were correlated with central and total fat
mass, while sCD36 and oxLDL correlated
with measures of insulin sensitivity inde-
pendent of BMI and central fat mass. Pio-
glitazone treatment reduced sCD36 while
improving insulin-stimulated glucose
metabolism, further supporting the asso-
ciation between insulin sensitivity and
sCD36 in PCOS.
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